Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 57

1.

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators.

N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21.

PMID:
26196665
2.

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD; UNITY-1 Study Group.

JAMA. 2015 May 5;313(17):1728-35. doi: 10.1001/jama.2015.3860.

PMID:
25942723
3.

Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse.

Ho SB, Bräu N, Cheung R, Liu L, Sanchez C, Sklar M, Phelps TE, Marcus SG, Wasil MM, Tisi A, Huynh L, Robinson SK, Gifford AL, Asch SM, Groessl EJ.

Clin Gastroenterol Hepatol. 2015 Feb 24. pii: S1542-3565(15)00161-5. doi: 10.1016/j.cgh.2015.02.022. [Epub ahead of print]

PMID:
25724704
4.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S.

Gut. 2015 Jun;64(6):948-56. doi: 10.1136/gutjnl-2014-307498. Epub 2014 Jul 30.

PMID:
25080450
5.

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators.

N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.

6.

Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.

Melia MT, Bräu N, Poordad F, Lawitz EJ, Shiffman ML, McHutchison JG, Muir AJ, Galler GW, Nyberg LM, Lee WM, Schiff E, Long J, Noviello S, Brass CA, Pedicone LD, Sulkowski MS.

Clin Infect Dis. 2014 Apr;58(7):960-9. doi: 10.1093/cid/ciu009. Epub 2014 Jan 6.

7.

Impact of hepatitis C treatment initiation on adherence to concomitant medications.

Pizzirusso M, Lin J, Head C, Marcus SM, Ahmed S, Bräu N, Weiss JJ.

J Assoc Nurses AIDS Care. 2014 Jan-Feb;25(1):23-31. doi: 10.1016/j.jana.2013.07.004. Epub 2013 Sep 24.

8.

Increasing antiviral treatment through integrated hepatitis C care: a randomized multicenter trial.

Groessl EJ, Sklar M, Cheung RC, Bräu N, Ho SB.

Contemp Clin Trials. 2013 Jul;35(2):97-107. doi: 10.1016/j.cct.2013.05.002. Epub 2013 May 10.

PMID:
23669414
9.

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.

Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, Dickson R, Tice A, Kulkarni R, Vierling JM, Lou Munson M, Chen YC, Najera I, Thommes J; JUMP-C Investigators.

Hepatology. 2013 Aug;58(2):514-23. doi: 10.1002/hep.26275. Epub 2013 Jun 24.

PMID:
23359491
10.

Evaluation of the hepatitis C virus-infected patient: the initial encounter.

Bräu N.

Clin Infect Dis. 2013 Mar;56(6):853-60. doi: 10.1093/cid/cis957. Epub 2012 Dec 12. Review.

11.

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hézode C, Lim JK, Bronowicki JP, Abrams GA, Bräu N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S.

Lancet Infect Dis. 2012 Sep;12(9):671-7. doi: 10.1016/S1473-3099(12)70138-X. Epub 2012 Jun 18.

PMID:
22714001
12.

Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.

Monteagudo-Chu MO, Chang MH, Fung HB, Bräu N.

J Pharm Pract. 2012 Oct;25(5):552-9. Epub 2012 May 2.

PMID:
22551561
13.

FIB-4 index is associated with hepatocellular carcinoma risk in HIV-infected patients.

Park LS, Tate JP, Justice AC, Lo Re V 3rd, Lim JK, Bräu N, Brown ST, Butt AA, Gibert C, Goetz MB, Rimland D, Rodriguez-Barradas MC, Dubrow R.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2512-7. doi: 10.1158/1055-9965.EPI-11-0582. Epub 2011 Oct 25.

14.

Racial differences in hepatitis C treatment eligibility.

Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; IDEAL Study Team.

Hepatology. 2011 Jul;54(1):70-8. doi: 10.1002/hep.24358.

15.

Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients.

Vachon ML, Factor SH, Branch AD, Fiel MI, Rodriguez-Torres M, Bräu N, Sterling RK, Slim J, Talal AH, Dieterich DT, Sulkowski MS.

J Hepatol. 2011 Jan;54(1):41-7. doi: 10.1016/j.jhep.2010.06.025. Epub 2010 Aug 21.

16.

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.

Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K, Deng W, Noviello S, Pedicone LD, Brass CA, Albrecht JK, McHutchison JG; IDEAL Study Team.

Gastroenterology. 2010 Nov;139(5):1602-11, 1611.e1. doi: 10.1053/j.gastro.2010.07.059. Epub 2010 Aug 16.

PMID:
20723545
17.

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R, Rasenack JW, Kryczka W, Lee CM, Bain VG, Pianko S, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-2/3 Study Team.

Gastroenterology. 2010 Oct;139(4):1267-76. doi: 10.1053/j.gastro.2010.06.062. Epub 2010 Jul 1.

18.

In memoriam: Edmund J. Bini, MD, MPH (1967-2010).

Bräu N.

Dig Dis Sci. 2010 May;55(5):1193. doi: 10.1007/s10620-010-1224-3. No abstract available.

PMID:
20383583
19.

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.

McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, Rockey D, Husa P, Chuang WL, Levine R, Jonas M, Theodore D, Brigandi R, Webster A, Schultz M, Watson H, Stancil B, Gardner S; Farglitizar Study Investigators.

Gastroenterology. 2010 Apr;138(4):1365-73, 1373.e1-2. doi: 10.1053/j.gastro.2009.12.003. Epub 2010 Feb 13. Erratum in: Gastroenterology. 2010 Jul;139(1):360.

PMID:
20004661
20.

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team.

N Engl J Med. 2009 Aug 6;361(6):580-93. doi: 10.1056/NEJMoa0808010. Epub 2009 Jul 22. Erratum in: N Engl J Med. 2009 Sep 3;361(10):1027.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk